<DOC>
	<DOCNO>NCT00473889</DOCNO>
	<brief_summary>This Phase III clinical trial incorporate initial Phase II component determine survival advance Non-small cell lung cancer patient treat MK0683 paclitaxel plus carboplatin</brief_summary>
	<brief_title>A Clinical Trial Vorinostat ( MK0683 , SAHA ) Combination With FDA Approved Cancer Drugs Patients With Advanced Non-Small Cell Lung Cancer ( NSCLC ) ( 0683-056 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Males female least 18 year age confirm diagnosis Nonsmall Cell Lung Cancer Patients systemic prior systemic treatment lung cancer except patient least 12 month prior adjuvant therapy Adequate bone marrow , kidney liver function Must recover least 4 week major surgery radiation ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 Men woman must agree use birth control study Women able child must negative pregnancy test 14 day study enrollment Patients prior treatment investigational agent le 4 week study enrollment Pregnant nursing female patient Patients HIV positive Patients Hepatitis A , B , C Patients unable take study medication mouth Patients untreated brain cancer Patient eligible treatment bevacizumab bevacizumab available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>